Humana Inc. (HUM) Stock Analysis
Is HUM a good investment?
Humana Inc. (HUM) has a Plutrex AI rating of 66.0/100 as of August 21, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: PEG ratio of 1.29x is 34.8% below the industry average of 1.98x — HUM offers the most growth per valuation dollar in managed care, with next-year EPS growth of 82.6% being 102.1% above the industry average of 40.9%; if the recovery materializes, forward P/E collapses to ~19.7x. Main concern: Profitability remains deeply distressed and UNCHANGED: net margin 0.9% (-21.1% vs. industry), operating margin 3.5% (-19.5% vs. industry), ROE 6.8% (-17.8% vs. industry) — the 82.6% EPS recovery is entirely dependent on CMS Stars ratings improvement (partially outside management control) and medical cost ratio normalization; the headline 'Can Humana's Star Ratings Rebound Unlock MA Earnings Power?' confirms this remains an open question, not a resolved one.
Investment Summary
Humana (HUM) at $380.73 remains a Hold — a recovery story with a credible but unproven thesis, now trading slightly below last week's $384.97 but still above the prior entry zone of $362-$378. The stock has pulled back -1.1% since the prior report, modestly improving the risk/reward but not enough to trigger a Buy. Core thesis: HUM is priced for an 82.6% EPS recovery next year from a deeply depressed base (net margin 0.9%, operating margin 3.5%, ROE 6.8% — all below the industry averages of 1.1%, 4.3%, and 8.3% respectively). The P/E of 36.05x on trough earnings is elevated vs. the industry average of 29.98x (+20.3% premium), but the PEG of 1.29x is 34.8% below the industry average of 1.98x — the most compelling relative valuation argument. Analyst consensus target of $418.46 implies 9.9% upside from current price. The $23.87B cash position and $1.94B FCF provide balance sheet protection. News flow is constructive: new Medicaid President hire (James 'J.P.' Holland) signals strategic diversification, and the headline 'U.S. Health Insurers Raise Outlooks Despite Q2 Cost Rises' suggests sector-wide stabilization. However, the Star Ratings rebound question ('Can Humana's Star Ratings Rebound Unlock MA Earnings Power?') remains the critical unresolved catalyst — without Stars improvement, the 82.6% EPS recovery is at risk.
Key Strengths
- PEG ratio of 1.29x is 34.8% below the industry average of 1.98x — HUM offers the most growth per valuation dollar in managed care, with next-year EPS growth of 82.6% being 102.1% above the industry average of 40.9%; if the recovery materializes, forward P/E collapses to ~19.7x
- Fortress balance sheet: $23.87B cash, $1.94B positive FCF, and debt-to-equity of 0.62x (7.7% below industry average of 0.67x) provide multi-year runway to weather continued medical cost pressure without balance sheet stress; strategic Medicaid expansion (new SVP James 'J.P.' Holland) and competitor MA market exits create consolidation opportunities
- Revenue growth of 26.2% is 32.1% above the industry average of 19.8%, demonstrating market share gains even during the profitability trough; sector headline 'U.S. Health Insurers Raise Outlooks Despite Q2 Cost Rises' suggests industry-wide stabilization that could accelerate HUM's recovery timeline
Key Concerns
- Profitability remains deeply distressed and UNCHANGED: net margin 0.9% (-21.1% vs. industry), operating margin 3.5% (-19.5% vs. industry), ROE 6.8% (-17.8% vs. industry) — the 82.6% EPS recovery is entirely dependent on CMS Stars ratings improvement (partially outside management control) and medical cost ratio normalization; the headline 'Can Humana's Star Ratings Rebound Unlock MA Earnings Power?' confirms this remains an open question, not a resolved one
- Valuation risk/reward remains asymmetric at current price: P/E of 36.05x is 20.3% above the industry average of 29.98x on trough earnings; analyst consensus target of $418.46 implies only 9.9% upside vs. potential 15-20% downside if EPS recovery is delayed; the prior entry zone of $362-$378 has been partially re-approached (stock at $380.73) but not fully reached, and the insider fiduciary duty headline ('Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?') adds governance uncertainty
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
HUM's fundamentals remain bifurcated between a stressed present and a projected recovery future. Current profitability is deeply below-average: net margin 0.9% vs. industry 1.1% (-21.1%), operating margin 3.5% vs. industry 4.3% (-19.5%), ROE 6.8% vs. industry 8.3% (-17.8%). These metrics are UNCHANGED from the prior report — no improvement has materialized. The P/E of 36.05x (down from 36.46x last week, -1.1%) remains a 20.3% premium to the industry average of 29.98x, unjustifiable on current earnings alone. The PEG of 1.29x (down from 1.31x, -1.5%) is the primary valuation support — 34.8% below the industry average of 1.98x — reflecting the market's pricing of the 82.6% next-year EPS recovery. Revenue growth of 26.2% (32.1% above industry average of 19.8%) confirms top-line momentum. Balance sheet is solid: debt-to-equity 0.62x (vs. industry 0.67x), $23.87B cash, $1.94B FCF. The forward recovery thesis hinges on CMS Stars ratings improvement and medical cost ratio normalization — both partially outside management control. If the 82.6% EPS recovery materializes, forward P/E drops to approximately 19.7x, making the stock attractively valued. If delayed, the 36x P/E on trough earnings is indefensible.
News Sentiment
Humana is navigating one of the most critical periods in its history, and the latest news suggests the healthcare giant is quietly repositioning for a comeback — even as questions about its profitability linger. The company made a significant leadership move this week, appointing James 'J.P.' Holland as Senior Vice President and President of Medicaid, effective August 17. Holland will oversee Humana's iCare subsidiary, which serves elderly and disabled populations in Wisconsin through Family Care and Family Care Partnership programs — a signal that Humana is serious about diversifying beyond its troubled Medicare Advantage business. On the broader industry front, a key headline — 'U.S. Health Insurers Raise Outlooks Despite Q2 Cost Rises, Shifting Membership' — offers encouraging context: Humana's peers are finding ways to manage rising medical costs, suggesting the industry headwinds that crushed Humana's margins may be easing. The most pressing question for investors, captured in the headline 'Can Humana's Star Ratings Rebound Unlock MA Earnings Power?', is whether Humana can restore its Medicare Advantage Star Ratings — a government quality score that directly determines reimbursement bonuses worth billions. Meanwhile, a new Chief Medical Officer appointment (Dr. Shantanu Nundy) signals fresh clinical leadership to tackle the medical cost problem head-on. One cloud on the horizon: a headline questioning whether insiders 'breached fiduciary duties' introduces governance uncertainty. Bottom line — Humana is making the right strategic moves, but the proof will be in the earnings recovery.
Risk Assessment
PRIMARY RISK: CMS Stars ratings failure — if HUM does not achieve Stars improvement for 2026 plan year, the 82.6% EPS recovery projection collapses, and the stock at 36x trough earnings faces 20-30% downside to $265-$305. SECONDARY RISK: Medical cost ratio re-acceleration — any spike in utilization (flu season, new high-cost therapies) could push the already-thin 0.9% net margin to breakeven or losses. TERTIARY RISK: Governance/legal — the headline 'Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?' introduces litigation risk that could distract management and create headline volatility. MITIGATION: $23.87B cash and $1.94B FCF provide substantial buffer; stop-loss at $335 (-9.4% from entry $370) limits downside; position size of 3.0% reflects the binary nature of the recovery thesis. UPSIDE SCENARIO: Stars rebound + medical cost normalization → 82.6% EPS recovery → forward P/E of ~19.7x → stock re-rates to $418-$443 range (T1/T2 targets).
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is HUM a halal stock?
No, Humana Inc. (HUM) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for HUM?
Humana Inc. (HUM) has a Plutrex AI rating of 66.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is HUM a good investment?
According to Plutrex AI, HUM has a Buy rating (66.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in HUM?
US stocks like HUM can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in HUM?
Plutrex AI identifies the main risks for HUM by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.